IDEAS home Printed from https://ideas.repec.org/a/nat/natcom/v6y2015i1d10.1038_ncomms7471.html
   My bibliography  Save this article

Identification of FOXM1 as a therapeutic target in B-cell lineage acute lymphoblastic leukaemia

Author

Listed:
  • Maike Buchner

    (University of California San Francisco)

  • Eugene Park

    (University of California San Francisco
    University of Cambridge)

  • Huimin Geng

    (University of California San Francisco)

  • Lars Klemm

    (University of California San Francisco)

  • Johanna Flach

    (The Eli and Edythe Broad Center for Regenerative Medicine and Stem Cell Research, University of California San Francisco)

  • Emmanuelle Passegué

    (The Eli and Edythe Broad Center for Regenerative Medicine and Stem Cell Research, University of California San Francisco)

  • Hilde Schjerven

    (University of California San Francisco)

  • Ari Melnick

    (Weill Cornell Medical College)

  • Elisabeth Paietta

    (Montefiore Medical Center, Albert Einstein College of Medicine)

  • Dragana Kopanja

    (University of Illinois at Chicago)

  • Pradip Raychaudhuri

    (University of Illinois at Chicago)

  • Markus Müschen

    (University of California San Francisco
    University of Cambridge)

Abstract

Despite recent advances in the cure rate of acute lymphoblastic leukaemia (ALL), the prognosis for patients with relapsed ALL remains poor. Here we identify FOXM1 as a candidate responsible for an aggressive clinical course. We show that FOXM1 levels peak at the pre-B-cell receptor checkpoint but are dispensable for normal B-cell development. Compared with normal B-cell populations, FOXM1 levels are 2- to 60-fold higher in ALL cells and are predictive of poor outcome in ALL patients. FOXM1 is negatively regulated by FOXO3A, supports cell survival, drug resistance, colony formation and proliferation in vitro, and promotes leukemogenesis in vivo. Two complementary approaches of pharmacological FOXM1 inhibition—(i) FOXM1 transcriptional inactivation using the thiazole antibiotic thiostrepton and (ii) an FOXM1 inhibiting ARF-derived peptide—recapitulate the findings of genetic FOXM1 deletion. Taken together, our data identify FOXM1 as a novel therapeutic target, and demonstrate feasibility of FOXM1 inhibition in ALL.

Suggested Citation

  • Maike Buchner & Eugene Park & Huimin Geng & Lars Klemm & Johanna Flach & Emmanuelle Passegué & Hilde Schjerven & Ari Melnick & Elisabeth Paietta & Dragana Kopanja & Pradip Raychaudhuri & Markus Müsche, 2015. "Identification of FOXM1 as a therapeutic target in B-cell lineage acute lymphoblastic leukaemia," Nature Communications, Nature, vol. 6(1), pages 1-14, May.
    • Handle: RePEc:nat:natcom:v:6:y:2015:i:1:d:10.1038_ncomms7471
    DOI: 10.1038/ncomms7471
    as

    Download full text from publisher

    File URL: https://www.nature.com/articles/ncomms7471
    File Function: Abstract
    Download Restriction: no
    File URL: https://libkey.io/10.1038/ncomms7471?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:6:y:2015:i:1:d:10.1038_ncomms7471. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.